The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Alphagan     5-bromo-N-(4,5-dihydro-1H- imidazol-2...

Synonyms: Alphagan (TN), SureCN265607, SureCN679153, CHEMBL1200389, AC1L1GYC, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of D02076


High impact information on D02076


Chemical compound and disease context of D02076


Biological context of D02076


Anatomical context of D02076


Associations of D02076 with other chemical compounds


Gene context of D02076

  • SETTING: Ophthalmic Health Center, Tel Aviv, Israel. METHODS: The pupil size was measured in 36 eyes of 36 participants under scotopic and photopic conditions using the Colvard pupillometer (Oasis Medical) before and after brimonidine tartrate drops were administered [4].

Analytical, diagnostic and therapeutic context of D02076


  1. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2. LeBlanc, R.P. Ophthalmology (1998) [Pubmed]
  2. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension. Reis, R., Queiroz, C.F., Santos, L.C., Avila, M.P., Magacho, L. Clinical therapeutics. (2006) [Pubmed]
  3. Anterior uveitis and concurrent allergic conjunctivitis associated with long-term use of topical 0.2% brimonidine tartrate. Becker, H.I., Walton, R.C., Diamant, J.I., Zegans, M.E. Arch. Ophthalmol. (2004) [Pubmed]
  4. Effect of brimonidine tartrate 0.2% ophthalmic solution on pupil size. Kesler, A., Shemesh, G., Rothkoff, L., Lazar, M. Journal of cataract and refractive surgery. (2004) [Pubmed]
  5. Retinal ganglion cell death induced by retinal ischemia. neuroprotective effects of two alpha-2 agonists. Vidal-Sanz, M., Lafuente, M.P., Mayor, S., de Imperial, J.M., Villegas-Pérez, M.P. Survey of ophthalmology. (2001) [Pubmed]
  6. Changes in intraocular pressure and ocular perfusion pressure after latanoprost 0.005% or brimonidine tartrate 0.2% in normal-tension glaucoma patients. Liu, C.J., Ko, Y.C., Cheng, C.Y., Chiu, A.W., Chou, J.C., Hsu, W.M., Liu, J.H. Ophthalmology (2002) [Pubmed]
  7. Vitreous concentration of topically applied brimonidine tartrate 0.2%. Kent, A.R., Nussdorf, J.D., David, R., Tyson, F., Small, D., Fellows, D. Ophthalmology (2001) [Pubmed]
  8. Neuroprotective effects of brimonidine treatment in a rodent model of ischemic optic neuropathy. Danylkova, N.O., Alcala, S.R., Pomeranz, H.D., McLoon, L.K. Exp. Eye Res. (2007) [Pubmed]
  9. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Sherwood, M.B., Craven, E.R., Chou, C., DuBiner, H.B., Batoosingh, A.L., Schiffman, R.M., Whitcup, S.M. Arch. Ophthalmol. (2006) [Pubmed]
  10. Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs. Eisenberg, D.L., Toris, C.B., Camras, C.B. Survey of ophthalmology. (2002) [Pubmed]
  11. Efficacy of bimatoprost 0.03 percent in untreated glaucoma and ocular hypertension patients: results from a large community-based clinical trial. Quinones, R., Severin, T., Mundorf, T. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. (2004) [Pubmed]
  12. Deepening of lid sulcus from topical bimatoprost therapy. Peplinski, L.S., Albiani Smith, K. Optometry and vision science : official publication of the American Academy of Optometry. (2004) [Pubmed]
  13. Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0.2% and betaxolol 0.25% suspension in patients with open-angle glaucoma and ocular hypertension. Brimonidine Outcomes Study Group II. Javitt, J., Goldberg, I. Journal of glaucoma. (2000) [Pubmed]
  14. Comparative acute effects of brimonidine 0.2% versus dorzolamide 2% combined with beta-blockers in glaucoma. Centofanti, M., Manni, G., Gregori, D., Cocco, F., Lorenzano, D., Bucci, M.G. Graefes Arch. Clin. Exp. Ophthalmol. (2000) [Pubmed]
  15. Brimonidine tartrate: a one-month dose response study. Derick, R.J., Robin, A.L., Walters, T.R., Barnebey, H.S., Choplin, N., Schuman, J., Kelley, E.P., Chen, K., Stoecker, J.F. Ophthalmology (1997) [Pubmed]
  16. Effect of brimonidine tartrate on ocular hemodynamic measurements. Lachkar, Y., Migdal, C., Dhanjil, S. Arch. Ophthalmol. (1998) [Pubmed]
  17. The effect of daily use of brimonidine tartrate on the dark-adapted pupil diameter. Brown, S.M., Khanani, A.M., McCartney, D.L. Am. J. Ophthalmol. (2004) [Pubmed]
  18. The efficacy of topical administration of brimonidine to reduce ischaemia in the very early stage of diabetic retinopathy in good controlled type-2 diabetes mellitus. Mondal, L.K., Baidya, K.P., Bhattacharya, B., Chatterjee, P.R., Bhaduri, G. Journal of the Indian Medical Association. (2004) [Pubmed]
  19. Development of an HPLC method for determining the alpha 2-adrenergic receptor agonist brimonidine in blood serum and aqueous humor of the eye. Karamanos, N.K., Lamari, F., Katsimpris, J., Gartaganis, S. Biomed. Chromatogr. (1999) [Pubmed]
  20. Vasoactive properties of bimatoprost in isolated porcine ciliary arteries. Allemann, R., Flammer, J., Haefliger, I.O. Klinische Monatsblätter für Augenheilkunde. (2003) [Pubmed]
  21. Hypertrichosis of the eyelashes caused by bimatoprost. Tosti, A., Pazzaglia, M., Voudouris, S., Tosti, G. J. Am. Acad. Dermatol. (2004) [Pubmed]
  22. Effect of different dose schedules of bimatoprost on intraocular pressure and pupil size in the glaucomatous Beagle. Gelatt, K.N., Mackay, E.O. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. (2002) [Pubmed]
  23. Estimated comparative costs of achieving a 20% reduction in intraocular pressure with bimatoprost or latanoprost in patients with glaucoma or ocular hypertension. Fiscella, R., Walt, J. Drugs & aging. (2006) [Pubmed]
  24. Selectivity of site of action and systemic effects of topical alpha agonists. Robin, A.L., Burnstein, Y. Current opinion in ophthalmology. (1998) [Pubmed]
  25. The adverse effect of perioperative brimonidine tartrate 0.2% on flap adherence and enhancement rates in laser in situ keratomileusis patients. Walter, K.A., Gilbert, D.D. Ophthalmology (2001) [Pubmed]
  26. Effects of brimonidine on aqueous humor dynamics in human eyes. Toris, C.B., Gleason, M.L., Camras, C.B., Yablonski, M.E. Arch. Ophthalmol. (1995) [Pubmed]
  27. Efficacy of brimonidine 0.2% in controlling acute postoperative intraocular pressure elevation after phacoemulsification. Katsimpris, J.M., Siganos, D., Konstas, A.G., PhD, n.u.l.l., Kozobolis, V., Georgiadis, N. Journal of cataract and refractive surgery. (2003) [Pubmed]
  28. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies. Walters, T.R. Survey of ophthalmology. (1996) [Pubmed]
WikiGenes - Universities